In summary, we show the usefulness in sampling from the extremes of UK Biobank data to identify novel genetic signatures underlying phenotypes important in the development of airway disease and smoking behaviour. The ongoing genotyping, and further phenotyping, of the rest of the UK Biobank resource will facilitate further GWAS, which will undoubtedly improve our understanding of the genetic and molecular basis of common disease.
